Peptide comparison
Selank vs Semax: How the Two Nootropic Peptides Actually Compare
A careful Selank vs Semax comparison: tuftsin vs ACTH origins, GABA vs BDNF mechanisms, the shared fMRI study, limited Russian evidence, and FDA status.
Selank and Semax are almost always mentioned in the same breath. They are both synthetic Russian-developed peptides, both usually sold online as nootropics, and both discussed in the same forums and product pages. That pairing makes a natural question: are they basically the same thing, or do they actually differ?
They are related in style but different in design. Selank comes from a different parent peptide than Semax, and the research literature frames the two around different problems and different mechanisms. This page compares what each peptide is, what its mechanistic and human evidence looks like, and where both run into the same hard limit: neither is an FDA-approved U.S. medicine, and most of the clinical record is Russian-language and not FDA-reviewed.
This is a comparison of evidence and claims, not a recommendation. It does not provide dosing, routes, stacks, or sourcing guidance for either peptide.
Comparison Snapshot
| Feature | Selank | Semax |
|---|---|---|
| Peptide family | Synthetic heptapeptide derived from the immune peptide tuftsin, with a Pro-Gly-Pro extension. | Synthetic peptide built from an ACTH(4-7) fragment plus a Pro-Gly-Pro tail. |
| Research framing | Most often discussed around anxiety, calmness, and GABA-related signaling. | Most often discussed around attention, stroke-context recovery, and neurotrophin biology. |
| Headline mechanism | Mechanistic papers describe effects on GABAergic gene expression and enkephalin handling. | Mechanistic papers describe upregulation of BDNF and its TrkB receptor. |
| Human data | Limited; a small healthy-volunteer imaging study and regional Russian clinical literature. | Limited; regional Russian clinical and stroke literature, plus the same imaging study. |
| U.S. regulatory status | No FDA-approved U.S. medicine identified. | No FDA-approved U.S. medicine identified. |
Different Origins
The clearest difference is where each molecule comes from. Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immune-modulating peptide, with an added Pro-Gly-Pro fragment that improves stability. Semax is built differently: it pairs a fragment of adrenocorticotropic hormone, the ACTH(4-7) sequence, with the same kind of Pro-Gly-Pro tail.
That shared Pro-Gly-Pro motif is part of why the two are so often grouped together, and it is a genuine design similarity. But the parent molecules point in different directions. Tuftsin biology connects Selank to immune and anxiety-related research, while the ACTH fragment connects Semax to stress-hormone and neurotrophin research. The names are not interchangeable, and treating them as one "Russian nootropic peptide" flattens a real distinction.
Both belong to the broader neurobiology peptide group on this site, alongside compounds like DSIP. Sitting in the same category is not the same as having the same evidence, mechanism, or product quality.
Different Proposed Mechanisms
The mechanism stories diverge as much as the origins. Selank's research is concentrated around GABAergic signaling. A PubMed-indexed paper on peptide-based anxiolytics discusses Selank's modulation of GABA receptor binding, and separate Frontiers in Pharmacology work reports that Selank administration affects the expression of genes involved in GABAergic neurotransmission. A related cell study examined how GABA, Selank, and olanzapine influence those same gene-expression pathways. Selank is also discussed in connection with the enkephalin system and serotonergic signaling.
Semax's mechanism story centers on neurotrophins instead. A Brain Research paper reported that Semax, an ACTH(4-10) analog, regulates BDNF and TrkB expression in the rat hippocampus. Follow-up work compared the temporary dynamics of NGF and BDNF gene expression under Semax, and a more recent paper described Semax and its Pro-Gly-Pro component activating neurotrophin transcription after cerebral ischemia. That is why Semax tends to be framed around attention, learning, and stroke-context recovery rather than anxiety.
Even at the mechanism level these are different tools. One body of work points toward inhibitory GABA-related signaling; the other points toward neurotrophic, BDNF-related signaling. Marketing that promises both peptides do the same thing is glossing over the research it claims to cite.
The One Shared Human Study
There is a single accessible English-language human study that tested the two head to head. A 2020 paper in Doklady Biological Sciences used a functional connectomic approach to assess Selank and Semax effects on resting-state brain connectivity in 52 healthy participants, with fMRI before injection and at 5 and 20 minutes afterward.
The study reported both general and specific effects on connectivity between the right amygdala and the right temporal cortex, and it described differing time-course patterns between the Selank and Semax groups. That is useful: it is human neuroimaging, and it shows the two peptides are distinguishable on a measurable brain endpoint rather than identical.
It is also limited in exactly the way these studies usually are. The participants were healthy volunteers, not people with a diagnosed condition. Resting-state connectivity is a biological readout, not a clinical outcome. The study does not show that either peptide reliably reduces anxiety, sharpens focus, or improves any symptom in a patient population. It tells us the two molecules act differently in the brain, not that either one works as advertised.
Shared Evidence Limits
Despite their differences, Selank and Semax share the same core weakness: the human evidence is thin and largely Russian-language. Both are approved or used clinically in Russia, and both have regional clinical literature, including a Russian-language article on Selank in anxiety disorders. That literature is real, but it differs from the large, replicated, regulator-reviewed evidence packages behind widely approved Western medicines in trial design, publication access, comparator choice, replication, and adverse-event reporting.
Most of the rest of the record for both peptides is mechanistic or animal work. Gene-expression changes in cells, BDNF dynamics in rat brain, and receptor-binding effects all help explain plausibility, but they sit lower on the evidence ladder than blinded human outcome trials. The how to read a peptide study guide walks through why a cell or rodent result should not be read as a human promise.
For a deeper single-peptide treatment, the Selank anxiety evidence review and the Semax stroke and nootropic review cover each molecule on its own. The honest summary for the comparison is that both have interesting mechanistic stories and limited human data, and neither has the evidence base of an established prescription drug.
Status, Safety, And Product Quality
On U.S. regulatory status, the two are in the same position: this review did not identify an FDA-approved U.S. medicine for either Selank or Semax. Without a U.S. label, neither has an FDA-reviewed indication, contraindication list, adverse-event table, drug-interaction section, route, or dosing schedule. Russian approval does not transfer to U.S. oversight.
FDA's general compounding guidance is relevant for both. Compounded drugs are not FDA-approved, and FDA does not review them for safety, quality, or effectiveness before marketing the way it reviews approved drugs. Many online Selank and Semax products are not compounded by a licensed pharmacy at all, and a research-labeled vial or nasal spray does not prove identity, sterility, concentration, route suitability, or medical appropriateness.
The name on a product, for either peptide, also does not settle the practical questions. Both are frequently sold as intranasal sprays, and this page gives no nasal-use, reconstitution, injection, storage, or dosing instructions for either. The reconstitution calculator can help with unit and concentration math, but it cannot verify what is actually in a vial. Anyone weighing one of these peptides against the other should do so with a qualified clinician, not on the basis of a comparison chart.
FAQ
Are Selank and Semax the same peptide? No. They share a Pro-Gly-Pro motif and a similar nootropic reputation, but Selank is tuftsin-derived and Semax is built from an ACTH fragment. Their proposed mechanisms differ too: GABA-related signaling for Selank, BDNF and neurotrophin signaling for Semax.
Is one better than the other? The evidence does not support a ranking. The research frames Selank around anxiety and Semax around attention and recovery, but human outcome data for both is limited, and neither has an FDA-reviewed label to compare against.
Can they be combined? This page does not provide stacking, dosing, or combination guidance. There is no human safety or interaction evidence here to support using them together, and both interact with central-nervous-system pathways that warrant caution.
Are either approved in the United States? No FDA-approved U.S. medicine was identified for Selank or Semax in the sources used for this page.
References
- Functional Connectomic Approach to Studying Selank and Semax Effects, Doklady Biological Sciences / PubMed.
- Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity, Protein and Peptide Letters / PubMed.
- Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission, Frontiers in Pharmacology / PubMed.
- GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells, Frontiers in Pharmacology / PubMed.
- Semax, an Analog of ACTH(4-10) with Cognitive Effects, Regulates BDNF and trkB Expression in the Rat Hippocampus, Brain Research / PubMed.
- Comparison of the Temporary Dynamics of NGF and BDNF Gene Expression in Rat Hippocampus, Frontal Cortex, and Retina under Semax Action, Molecular Biology / PubMed.
- Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia, International Journal of Molecular Sciences / PMC.
- The Use of Selank in the Treatment of Anxiety Disorders, Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova / PubMed.
- Compounding and the FDA: Questions and Answers, U.S. Food and Drug Administration.
Disclaimer
This page is educational and is not medical advice. It does not provide dosing, nasal-use instructions, injection instructions, reconstitution instructions, compounding guidance, sourcing advice, anxiety or cognitive treatment, medication-substitution guidance, or individualized medical recommendations for Selank, Semax, or related products. Mental-health symptoms, cognitive concerns, medication changes, and peptide-product decisions should be discussed with qualified healthcare professionals using current regulator-reviewed information.
Next steps
Continue with the closest guide, peptide profile, or research tool.
